Bison Botanics

In August 2026, Bison Botanics concentrated 43.26% of sales in Flower with a year-over-year decline of 34.73% but a month-over-month lift of 3.35%, while Vapor Pens carried 31.97% share with a milder year-over-year drop of 3.73% and a 3.23% month-over-month gain. Pre-Roll held 13.92% share despite a 49.48% year-over-year contraction, countered by a 14.03% month-over-month rebound; meanwhile Beverage at 5.77% share fell 46.64% year-over-year and 30.37% month-over-month. Tincture & Sublingual remained small at 1.32% share but spiked 250.87% month-over-month and 30.55% year-over-year, whereas Concentrates at 3.02% share slipped 8.00% month-over-month with no year-over-year read. The pattern implies a heavier tilt toward inhalables that are stabilizing month-over-month, while peripheral formats bifurcate between rapid Tincture & Sublingual trial and steep Beverage and Edible retreats of 30.37% and 57.27% month-over-month, respectively.

These shifts suggest Bison Botanics is increasingly anchored in inhalable use-cases where Vapor Pens outperformed Flower on a relative year-over-year basis by 31.00 percentage points (down 3.73% vs. down 34.73%) and Pre-Roll provided near-term momentum with a 14.03% month-over-month surge. With Beverage and Edible contracting 46.64% and 96.06% year-over-year, the brand’s differentiation is moving away from ingestibles toward faster-onset formats, while the 250.87% month-over-month spike in Tincture & Sublingual signals a niche activation that could diversify basket roles if sustained. Given an overall brand year-over-year sales change of -30.34% alongside a rank of 85 in Flower in New York, the mix implies that near-term share defense hinges on Vapor Pens and Pre-Roll pacing, with Flower requiring pricing or assortment tuning as its average price at $28.02 diverges from the brand’s average price shift of -0.69% year-over-year.